Member Info for Titania

missed:
' 6b. Slap around distributor for sloppy website ~done

It also seems to me that there are different segments in testing round Specificity, Sensitivity/ the level of Viral Load, time to results, ease of use, and cost. Sir Al did start discussing these in his video on Specificity and Sensitivity.

A cheap, fast test with high sensitivity at low viral loads but with higher false positives has real value. Does anyone get a sense if Condor gets this? Or are we running the risk of Condor looking for the Rolls Royce of testing?

I think that list did come from Laurence Kotlikoff and Michael Mina NY Times piece. But I have also seen a video of a TeraGroup piece of kit - have others seen this? Yes the latter is a machine but the turnaround time is seconds and the marginal cost is very low - just a tube. Will check out Gabe Olin’s question which I must have missed.

Who do we think are our major global competitors for a quick response test that does not require equipment? My starter list included:

E25Bio, Sherlock Biosciences, and Mammoth Biosciences.

Does anyone have a view of these players?

AIM. - All Investors Maimed.

Wonder whether they had a stop loss on and the MMs exploited it. ;-)

Of course I missed, Avacta is the next Synairgen.

Have the Americans arrived? Or is it just the "would not want to be out of this over the weekend" crowd. Or is it just a great time to buy Avacta?

Agree PSB123. Any idea how this is compliant with the FSA's policy: Statement of Policy: listed companies and recapitalisation issuances during the coronavirus crisis? (google it).

So why not resolution 9?

A V and a W feel like the same thing, until you are 50% through the W.

Does anyone else's Alexa occasionally respond to the mention of Avacta?

The swab test could have a false negative of up to 20% - from the House of Commons Health etc select committee, yesterday. Taking a swab is hard. This performance is problematic. Any sense on false negatives for saliva tests?

If the Cytiva tests were not working, would that be a material fact that would have to be disclosed in this placement? Does anyone know the AIM rules here?

If so, do we have a dog that has not barked in the night?

We might be 40% or so off the peak but we are up 40% or so in the last month. And anyone who did get shares in the placement is sitting on over a 100% return. It really depends on where you are coming from.

Has anyone seen the FCA's Statement of Policy: listed companies and recapitalisation issuances during the coronavirus crisis. Link below. This introduces the idea of Soft preemption rights.

Do investors think the recent Genedrive fundraising was compliant?

https://www.fca.org.uk/news/statements/listed-companies-recapitalisation-issuances-coronavirus

What would be the timing to get to an anti-viral? How fast track could this be done mice, phase 1, phase 2. Could this be ready by the winter - so we can avoid the nightmare flu + Covid discussed yesterday?

Also, if this works would the same approach allow tailored anti-virals for future viruses?

I suspect Landsdowne mark their listed positions to market - so they will not need to sell to recognise their profit. The issue that they probably face is redemption requests given their loss. While they will probably have a lock in period, they will need to sell assets across the board to fund these redemptions.

An OO does not comply with the principle of soft-preemption rights. For the note on this, google FCA Statement of Policy: listed companies and recapitalisation issuances during the coronavirus crisis.

I am sure there will be an RNS shortly. But the note also says:

The Bookrunners expect to notify stockbrokers of the number of Broker Option Shares they have been allocated later today by way of contract notes. Stockbrokers who have placed an order will receive a single allocation, and are in turn responsible for apportioning their allocation to their underlying clients and for confirming whether the shares should be EIS or VCT qualifying, any allocation being subject to the relevant limit of eligible shares.